By Professor David Thomas

Preprints

Collet L; Telouk P; Albarede F; Girodet M; Maqua C; Rogasik M; Ducimetière F; Tabone-Eglinger S; Brahmi M; Dufresne A; Thomas DM; Ballinger ML; Blay J-Y; Ray-Coquard I, 2023, Connecting the changing metallomic spectrum and survival in sarcoma: a pilot study, http://dx.doi.org/10.21203/rs.3.rs-3291225/v1

Walpole I; Zaman FY; Zhao P; Marshall VM; Lin F; Thomas DM; Shackleton M; Antolin AA; Ameratunga M, 2023, Computational repurposing of oncology drugs through off-target drug binding interactions from pharmacological databases, http://dx.doi.org/10.1101/2023.07.01.547311

Best M; Bartley N; Napier C; Fisher A; Ballinger M; Thomas D; Goldstein D; Tucker K; Biesecker B; Butow P, 2022, Return of comprehensive tumour genomic profiling results to advanced cancer patients: a qualitative study, http://dx.doi.org/10.21203/rs.3.rs-1190781/v1

Thavaneswaran S; Lin F; Kansara M; Grady J; Espinoza D; Joshua A; Grimison P; Craft P; Cosman R; Lee C; Harwood K; Chinchen S; Corpuz T; Ballinger M; Sebastian L; Simes J; Thomas D, 2022, A signal-seeking Phase II trial of Durvalumab and Tremelimumab Focused on Advanced, Rare and Less Common Cancers, http://dx.doi.org/10.1101/2022.06.30.22277092

Jadhao S; Davison C; Roulis EV; Lee S; Lacaze P; Riaz M; McNeil JJ; Thomas DM; Pecheniuk NM; Hyland CA; Flower RL; Nagaraj SH, 2021, Using Whole Genome Sequencing to Characterize Clinically Significant Blood Groups Among Healthy Older Australians, http://dx.doi.org/10.1101/2021.04.18.21255241

Thavaneswaran S; Sebastian L; Kansara M; Ballinger M; Espinoza D; Lin F; Lee C; Sjoquist K; Grady J; Cowley M; Joshua A; Qiu M; Oakes S; Simes J; Thomas D, 2021, A Signal-seeking Phase Iia Trial of Palbociclib in Advanced Cancers With Cell Cycle Pathway Alterations – A Substudy of the Molecular Screening and Therapeutics (Most) Program, http://dx.doi.org/10.21203/rs.3.rs-254137/v1

Kaur S; Sikta N; Schafferhans A; Bordin N; Cowley M; Thomas D; Ballinger M; O’Donoghue S, 2021, Streamlined use of protein structures in variant analysis, http://dx.doi.org/10.1101/2021.09.10.459756

Minoche AE; Lundie B; Peters GB; Ohnesorg T; Pinese M; Thomas DM; Zankl A; Roscioli T; Schonrock N; Kummerfeld S; Burnett L; Dinger ME; Cowley MJ, 2020, ClinSV: Clinical grade structural and copy number variant detection from whole genome sequencing data, http://dx.doi.org/10.1101/2020.06.30.20143453

Lin F; Thavaneswaran S; Grady J; Ballinger M; Kansara M; Oakes S; Desai J; Lee CK; Simes J; Thomas D, 2020, Criteria-based curation of a therapy-focused compendium to support treatment recommendations in precision oncology, http://dx.doi.org/10.1101/2020.12.18.20248521

Shin SJ; Dodd E; Peng G; Bojadzieva J; Chen J; Amos C; Mai PL; Savage SA; Ballinger ML; Thomas DM; Yuan Y; Strong LC; Wang W, 2019, Risk of differential cancer types over age in families with Li-Fraumeni syndrome: a validation study using multi-center cohorts, http://dx.doi.org/10.1101/567727

Puttick C; Kumar K; Davis R; Pinese M; Thomas D; Dinger M; Sue C; Cowley M, 2019, mity: A highly sensitive mitochondrial variant analysis pipeline for whole genome sequencing data, http://dx.doi.org/10.1101/852210

Lacaze P; Pinese M; Kaplan W; Stone A; Brion M-J; Woods RL; McNamara M; McNeil JJ; Dinger ME; Thomas DM, 2018, The Medical Genome Reference Bank: a whole-genome data resource of 4,000 healthy elderly individuals. Rationale and cohort design, http://dx.doi.org/10.1101/274019

Chan EKF; Petersen DC; Lyons RJ; Baldi BF; Papenfuss AT; Thomas DM; Hayes VM, 2017, Whole genome optical mapping reveals multiple fusion events chained by large novel sequences in cancer, http://dx.doi.org/10.1101/166173

Thomas DM; Wood MA, 2016, The Emergence of Negative Superhumps in Cataclysmic Variables: Smoothed Particle Hydrodynamics Simulations, http://dx.doi.org/10.48550/arxiv.1602.06314

Wood MA; Thomas DM; Simpson JC, 2009, SPH Simulations of Negative (Nodal) Superhumps: A Parametric Study, http://dx.doi.org/10.48550/arxiv.0906.2713

Back to profile page